Literature DB >> 36267367

An update of polycystic ovary syndrome: causes and therapeutics options.

Abeer M Rababa'h1, Bayan R Matani1, Alaa Yehya2.   

Abstract

Polycystic ovary syndrome (PCOS) is a heterogeneous disorder characterized by menstrual irregularities, chronic anovulation, hirsutism, androgenic alopecia, and acne. At diagnosis, patients can with different manifestations according to the disease phenotype, patient's age, and lifestyle. However, most patients pursue medical care because of the clinical symptoms of PCOS, such as hyperandrogenism, menstrual irregularities and infertility. Recent studies have shown that PCOS is associated with 80% of anovulatory infertility; however, the precise mechanism of PCOS-induced anovulation is still undetermined. The treatment strategies of PCOS are symptomatic depending mainly on the desired goals and clinical benefits. Life style intervention is still the first line treatment option for overweight females seeking pregnancy. In addition, there are many pharmacological agents that could be added to induce ovulation such as metformin, and clomiphene citrate. Nowadays, many patients preferred to use some herbal medicine that was proved to have potential therapeutic benefits in many studies in the management of PCOS. The purpose of this review was to discuss PCOS-induced infertility and the available therapeutic options as well as the impact of COVID-19 infection on the success of fertility attempts. To address this purpose, Pubmed, Scopus, EMBASE and Google databases were searched for studies discussing PCOS-induced infertility. The literature search revealed the proper therapeutic plans to treat PCOS-induced infertility, and that treatment should be modified according to patient's complaints, reproductive desires, and disease phenotypes. In conclusion, the use of specific therapeutic agents and patients' adherence to lifestyle interventions could help patients recover their reproductive and metabolic health.
© 2022 The Author(s).

Entities:  

Keywords:  Amenorrhea; Anovulation; Anti-müllerian hormone; Hyperandrogenism; Infertility; Pharmacology; Polycystic ovary syndrome

Year:  2022        PMID: 36267367      PMCID: PMC9576888          DOI: 10.1016/j.heliyon.2022.e11010

Source DB:  PubMed          Journal:  Heliyon        ISSN: 2405-8440


  113 in total

1.  Metformin therapy for the reproductive and metabolic consequences of polycystic ovary syndrome.

Authors:  Susan Sam; David A Ehrmann
Journal:  Diabetologia       Date:  2017-08-03       Impact factor: 10.122

Review 2.  Prevention and management of ovarian hyperstimulation syndrome.

Authors:  Scott M Nelson
Journal:  Thromb Res       Date:  2017-03       Impact factor: 3.944

Review 3.  Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.

Authors:  Lara C Morley; Thomas Tang; Ephia Yasmin; Robert J Norman; Adam H Balen
Journal:  Cochrane Database Syst Rev       Date:  2017-11-29

4.  Metabolic disease: New role for HDACs in glucose homeostasis.

Authors:  Sarah Crunkhorn
Journal:  Nat Rev Drug Discov       Date:  2011-07-01       Impact factor: 84.694

5.  Effects of bariatric surgery on patients with obesity and polycystic ovary syndrome: a meta-analysis.

Authors:  Zhao Tian; Yi-Chao Zhang; Yue Wang; Xiao-Hong Chang; Hong-Lan Zhu; Yan Zhao
Journal:  Surg Obes Relat Dis       Date:  2021-04-21       Impact factor: 4.734

Review 6.  PCOS remains a diagnosis of exclusion: a concise review of key endocrinopathies to exclude.

Authors:  Eleni Magdalini Kyritsi; George K Dimitriadis; Ioannis Kyrou; Gregory Kaltsas; Harpal S Randeva
Journal:  Clin Endocrinol (Oxf)       Date:  2016-10-11       Impact factor: 3.478

7.  Effects of Dietary Glycemic Index and Glycemic Load on Cardiometabolic and Reproductive Profiles in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Authors:  Maryam Kazemi; Amir Hadi; Roger A Pierson; Marla E Lujan; Gordon A Zello; Philip D Chilibeck
Journal:  Adv Nutr       Date:  2021-02-01       Impact factor: 8.701

Review 8.  Androgen receptor gene polymorphism and polycystic ovary syndrome.

Authors:  Lawrence H Lin; Maria C P Baracat; Gustavo A R Maciel; José M Soares; Edmund C Baracat
Journal:  Int J Gynaecol Obstet       Date:  2012-11-24       Impact factor: 3.561

9.  Hydroalcoholic extract of flaxseed improves polycystic ovary syndrome in a rat model.

Authors:  Gholamali Jelodar; Sajjad Masoomi; Farhad Rahmanifar
Journal:  Iran J Basic Med Sci       Date:  2018-06       Impact factor: 2.699

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.